Metastatic Adenocarcinoma of the Pancreas clinical trials at UCSF
1 in progress, 0 open to new patients
Sorry, in progress, not accepting new patients
The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).
San Francisco, California and other locations